Physician profile
Bryan Dahms
NPI 1891282646
$3,247.28
in general payments reported to CMS, 2019-2025
35 companies · $993 in 2025
The $993 reported for 2025 was more than what 86% of Family Medicine providers received nationally (typical 2025 total: $153).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $20.14 · 2020: $11.21 · 2021: $148 · 2022: $778 · 2023: $831 · 2024: $466 · 2025: $993.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $2,282 · Education: $7.96.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $2,282.27 |
| Education | $7.96 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbvie INC. | $609.47 | 2021-2025 | Vraylar, Ubrelvy, Linzess |
| Astrazeneca Pharmaceuticals LP | $426.52 | 2020-2025 | Breztri, Farxiga, Airsupra |
| Pfizer INC. | $311.82 | 2022-2025 | |
| Amgen INC. | $214.37 | 2021-2025 | Evenity, Otezla, Repatha |
| Iti, INC. (D/B/A Intra-Cellular Therapies, INC.) | $201.94 | 2022-2025 | Caplyta |
| Novartis Pharmaceuticals Corporation | $165.66 | 2022-2025 | |
| Glaxosmithkline, LLC. | $151.35 | 2022-2025 | Arexvy, Trelegy Ellipta, Shingrix |
| Novo Nordisk INC | $148.10 | 2022-2025 | Wegovy, Rybelsus, Ozempic |
| Exact Sciences Corporation | $138.63 | 2023-2025 | Cologuard Collection Kit |
| Lilly USA, LLC | $106.61 | 2021-2025 | Jardiance, Mounjaro, Zepbound |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $105.31 | 2022-2025 | Xifaxan, Trulance |
| Biohaven Pharmaceutical Holding Company LTD. | $81.11 | 2022 | |
| Teva Pharmaceuticals USA, INC. | $70.87 | 2022-2023 | Austedo, Austedo Xr |
| Otsuka America Pharmaceutical, INC. | $50.79 | 2025 | Rexulti |
| Bayer Healthcare Pharmaceuticals INC. | $37.73 | 2019-2022 |
Show all 35 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| E.R. Squibb & Sons, L.L.C. | $35.14 | 2022-2023 | Eliquis |
| Tms Neurohealth Centers INC. | $32.73 | 2025 | Tms Neurohealth Centers INC. |
| Inspire Medical Systems, INC. | $28.40 | 2023 | Inspire |
| Alvogen INC | $24.33 | 2025 | Teriparatide |
| Merck Sharp & Dohme LLC | $24.26 | 2021-2022 | |
| Vanda Pharmaceuticals INC. | $24.17 | 2025 | Fanapt |
| Supernus Pharmaceuticals, INC. | $23.77 | 2025 | Qelbree |
| Sage Therapeutics, LLC | $23.77 | 2025 | Zurzuvae |
| Dexcom, INC. | $21.57 | 2025 | Dexcom G6 Transmitter |
| Medtronic, INC. | $21.51 | 2025 | Venaseal |
| Agile Therapeutics, INC. | $20.92 | 2022 | |
| Horizon Therapeutics Plc | $19.72 | 2022 | |
| Acadia Pharmaceuticals INC | $19.31 | 2024 | Daybue |
| Eisai INC. | $18.52 | 2022 | |
| Mylan Specialty L.P. | $18.52 | 2023 | Yupelri |
| Daiichi Sankyo INC. | $16.72 | 2024 | Injectafer |
| Genentech USA, INC. | $16.49 | 2021 | |
| Abbott Laboratories | $13.49 | 2023 | Proclaim |
| Alnylam Pharmaceuticals INC. | $12.37 | 2022 | |
| Antares Pharma, INC. | $11.29 | 2021 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Bryan Dahms listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.